TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Vor Biopharma ( (VOR) ).
On September 17, 2025, Vor Biopharma Inc. announced a reverse stock split at a 1-for-20 ratio, approved by stockholders on August 25, 2025. Effective September 18, 2025, this move will consolidate every 20 shares into one, affecting stock options, warrants, and incentive plans proportionately, with trading on a split-adjusted basis starting September 19, 2025. This action aims to streamline the company’s stock structure without altering stockholder ownership percentages, potentially impacting market perception and stock liquidity.
The most recent analyst rating on (VOR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Biopharma Inc. operates in the biopharmaceutical industry, focusing on developing innovative therapies for cancer treatment. The company is known for its pioneering work in cell therapy and genetic engineering to create targeted treatments for hematological malignancies.
Average Trading Volume: 18,506,061
Technical Sentiment Signal: Buy
Current Market Cap: $202.7M
For an in-depth examination of VOR stock, go to TipRanks’ Overview page.